Development of a plasma-free amino acid-based risk score for the incidence of cardiovascular diseases in a general population: The Nagahama study.


Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 03 04 2023
revised: 02 10 2023
accepted: 23 10 2023
medline: 27 11 2023
pubmed: 6 11 2023
entrez: 3 11 2023
Statut: ppublish

Résumé

Levels of circulating amino acids (AAs) have been suggested to be associated with cardiovascular diseases (CVDs). This study aimed to develop a plasma-free amino acid (PFAA)-based CVD risk-prediction model in a general population. The study participants consisted of 9220 community residents (mean age, 53.2 years; standard deviation, 13.3 years). Circulating levels of 19 PFAAs were measured via high-performance liquid chromatography/electrospray ionization mass spectrometry. The incidence of CVDs was determined by reviewing participants' clinical records. The prediction model was developed using the Cox proportional hazards model with the brute force variable selection and then cross-validated. During the 8.5-year follow-up, 220 CVD events were observed. Six AAs (alanine, citrulline, glycine, histidine, serine, and tyrosine) were identified as components of the prediction model, of which the C-index was 0.72. The association between the fourth quartile of the risk score calculated using the prediction model and the CVD events was independent of conventional risk factors (adjusted hazard ratio [HR], 1.9; 95 % confidence interval, 1.1-3.3). When examining crude relationships between conventional risk factors and the PFAA-based risk score by subgroup analyses, the association was significant for most subpopulations, men [crude HR = 6.4 (2.0-20.2)] and women [crude HR = 4.9 (2.6-9.3)], and individuals with [crude HR = 4.7 (2.5-8.9)] and without [crude HR = 7.2 (2.7-18.9)] lifestyle-related diseases, but not for older (≥70 years) participants [crude HR = 3.3 (0.8-13.5)]. The risk score successfully identified at-risk individuals [HR = 2.1 (1.2-3.5)] from participants who were classified as low risk by a conventional CVD risk score. The PFAA-based risk score predicted CVD events independently of conventional risk factors.

Sections du résumé

BACKGROUND & AIMS OBJECTIVE
Levels of circulating amino acids (AAs) have been suggested to be associated with cardiovascular diseases (CVDs). This study aimed to develop a plasma-free amino acid (PFAA)-based CVD risk-prediction model in a general population.
METHODS METHODS
The study participants consisted of 9220 community residents (mean age, 53.2 years; standard deviation, 13.3 years). Circulating levels of 19 PFAAs were measured via high-performance liquid chromatography/electrospray ionization mass spectrometry. The incidence of CVDs was determined by reviewing participants' clinical records. The prediction model was developed using the Cox proportional hazards model with the brute force variable selection and then cross-validated.
RESULTS RESULTS
During the 8.5-year follow-up, 220 CVD events were observed. Six AAs (alanine, citrulline, glycine, histidine, serine, and tyrosine) were identified as components of the prediction model, of which the C-index was 0.72. The association between the fourth quartile of the risk score calculated using the prediction model and the CVD events was independent of conventional risk factors (adjusted hazard ratio [HR], 1.9; 95 % confidence interval, 1.1-3.3). When examining crude relationships between conventional risk factors and the PFAA-based risk score by subgroup analyses, the association was significant for most subpopulations, men [crude HR = 6.4 (2.0-20.2)] and women [crude HR = 4.9 (2.6-9.3)], and individuals with [crude HR = 4.7 (2.5-8.9)] and without [crude HR = 7.2 (2.7-18.9)] lifestyle-related diseases, but not for older (≥70 years) participants [crude HR = 3.3 (0.8-13.5)]. The risk score successfully identified at-risk individuals [HR = 2.1 (1.2-3.5)] from participants who were classified as low risk by a conventional CVD risk score.
CONCLUSIONS CONCLUSIONS
The PFAA-based risk score predicted CVD events independently of conventional risk factors.

Identifiants

pubmed: 37922695
pii: S0261-5614(23)00353-9
doi: 10.1016/j.clnu.2023.10.024
pii:
doi:

Substances chimiques

Citrulline 29VT07BGDA
Glycine TE7660XO1C
Amines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2512-2519

Investigateurs

Yasuharu Tabara (Y)
Takahisa Kawaguchi (T)
Kazuya Setoh (K)
Yoshimitsu Takahashi (Y)
Shinji Kosugi (S)
Takeo Nakayama (T)
Fumihiko Matsuda (F)

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest Plasma amino acid levels were measured by Ajinomoto Co., Inc. The Center for Genomic Medicine received research funding, and YT and FM received consultation fees from Ajinomoto Co., Inc. MT, HY, KN, AI, and YK are employees of Ajinomoto Co., Inc. This does not alter the authors’ adherence to all of the journal policies. No other potential conflicts of interest in relation to this article are declared.

Auteurs

Masamichi Takeshita (M)

Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi 210-8681, Japan. Electronic address: masamichi.takeshita.wn4@asv.ajinomoto.com.

Yasuharu Tabara (Y)

Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Shogoinkawara-cho, Sakyo-ku, Kyoto 606-8507, Japan; Graduate School of Public Health, Shizuoka Graduate University of Public Health, Kita-ando 4-27-2, Aoi-ku, Shizuoka 420-0881, Japan. Electronic address: tabara@s-sph.ac.jp.

Kazuya Setoh (K)

Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Shogoinkawara-cho, Sakyo-ku, Kyoto 606-8507, Japan; Graduate School of Public Health, Shizuoka Graduate University of Public Health, Kita-ando 4-27-2, Aoi-ku, Shizuoka 420-0881, Japan. Electronic address: kseto@s-sph.ac.jp.

Kenji Nagao (K)

Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi 210-8681, Japan. Electronic address: kenji.nagao.df2@asv.ajinomoto.com.

Akira Imaizumi (A)

Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi 210-8681, Japan. Electronic address: akira.imaizumi.2eh@asv.ajinomoto.com.

Yoko Kageyama (Y)

AminoIndex Department, Ajinomoto Co., Inc., 1-15-1, Kyobashi, Chuo-Ku, Tokyo 104-0031, Japan. Electronic address: yoko.kageyama.gp4@asv.ajinomoto.com.

Fumihiko Matsuda (F)

Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Shogoinkawara-cho, Sakyo-ku, Kyoto 606-8507, Japan. Electronic address: fumi@genome.med.kyoto-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH